Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 2;290(1):141–156. doi: 10.1111/joim.13234

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Fig. 3 — Development and screening of monoclonal human PC‐mAbs Flow cytometry demonstrates that unlike murine IgM anti‐PC(A), polyclonal anti‐PC IgG does not block oxLDL uptake by macrophages (b). Both IgG1 and IgG4 antibodies fail to display an inhibiting effect (c), excluding the potential enhanced Fc receptor‐regulated uptake of oxLDL (d) including Fc‐receptor blockade by anti‐CD32 and anti‐CD64 antibodies. Relative ranking of antibody affinity to PC (e) and oxLDL (f), measured through ELISA (expressed as OD). Flow cytometry of antibody affinity (g) for live cells (annexin V−PI−), early apoptotic cells (annexin V+PI−) and late apoptotic cells (annexin V+PI+), expressed as mean fluorescent intensity of each cell population. (h) CCL2 release assay of human monocytes stimulated with oxLDL alone or in combination with antibody clones, results of 2 individual experiments. One‐way ANOVA.